Drug
DLBS 1033 clinical trials
Also written DLBS1033.
Keep track of what changes. Save the DLBS 1033 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2020 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 8
Dexa Medica Group (8) · Universitas Sebelas Maret (4) · Indonesia University (2) · RS H Adam Malik (1) · Duta Wacana Christian University (1)
Studies
Open first, then newest update. How each study uses DLBS 1033 is read from its arms, and is right about nine times in ten.
Testing it · 16
- DLBS1033 as Adjunctive Therapy for Patients With Diabetic NeuropathyNot yet recruitingNot applicableRS H Adam MalikNCT07683598Written as DLBS1033
- The Effect of Oral DLBS1033 in Patients With Diabetic PolyneuropathyNot yet recruitingPhase 2/3Universitas Sebelas MaretNCT07475065Written as DLBS1033
- Effects of Lumbrokinase DLBS1033 on D-Dimer, Interleukin-6, and Clinical Outcomes in Patients With Pneumonia and SepsisCompletedPhase 2Universitas Sebelas MaretNCT07892794Written as DLBS1033
- Oral DLBS1033 as Adjunctive Therapy in Acute Ischemic Stroke: Impact on Inflammatory Biomarkers and OutcomesCompletedPhase 4Universitas Sebelas MaretNCT07121569Written as Oral lumbrokinase DLBS1033
- Comparing Oral Lumbrokinase DLBS1033 and Betahistine Mesylate in Benign Paroxysmal Positional VertigoCompletedPhase 4Universitas Sebelas MaretNCT07075289Written as DLBS1033
- DLBS1033 for Acute Ischemic Stroke PatientsTerminatedPhase 2/3Dexa Medica GroupNCT02133521Written as DLBS1033
- Effect of DLBS1033 After Primary PCI in Patients With STE-ACSTerminatedPhase 2/3Dexa Medica GroupNCT02976701Written as DLBS1033
- The Benefit of Add On DLBS1033 for Ischemic Stroke PatientStatus unknownPhase 2/3Duta Wacana Christian UniversityNCT04425590Written as DLBS1033
- DLBS1033 Treatment in Diabetic With Peripheral Arterial DiseaseTerminatedPhase 2/3Dexa Medica GroupNCT02145988Written as DLBS1033
- The Effects of DLBS1033 on Haemostasis Parameters in Healthy VolunteersCompletedPhase 2Indonesia UniversityNCT01694537Written as DLBS1033
- Biological Half Life of DLBS1033 in Healthy VolunteersCompletedPhase 1/2Indonesia UniversityNCT01905878Written as DLBS1033
- DLBS1033 for the Treatment of Acute Ischemic StrokeTerminatedPhase 3Dexa Medica GroupNCT02362984Written as DLBS1033
- Efficacy and Safety of DLBS1033 in Subjects With Type 2 Diabetes MellitusCompletedPhase 4Dexa Medica GroupNCT01865474Written as DLBS1033
- DLBS1033 for Acute NSTEMI Without Early Coronary RevascularizationWithdrawnPhase 2/3Dexa Medica GroupNCT02146664Written as DLBS1033
- Efficacy of DLBS1033 in Patients With Acute Ischemic StrokeCompletedPhase 3Dexa Medica GroupNCT01790997Written as DLBS1033
- Safety and Efficacy of DLBS1033 in Healthy SubjectsCompletedNot applicableDexa Medica GroupNCT01378585Written as DLBS1033
Codes
What other systems call DLBS 1033 · ClinicalTrials.gg INT005853
- MeSH (NLM) C559131DLBS 1033One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C559131 | DLBS 1033 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.